FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016175056> ?p ?o ?g. }

• W2016175056 endingPage "545" @default.
• W2016175056 startingPage "539" @default.
• W2016175056 abstract "Two hundred and forty cadaveric renal transplant recipients given anti-thymocyte globulin (Thymoglobulin) as induction immunotherapy were followed up prospectively to review safety and efficacy.The median number of infusions was 10 [2-21] with a cumulative dose of 8.8 mg/kg [2.0-23.2 mg/kg]. During the fortnight following transplantation, 231 patients (96%) received a calcineurin inhibitor; all patients were given steroids and azathioprine or mycophenolate mofetil. At 1 yr, 60% of patients were on tripletherapy, 38% on bitherapy, and 2% on monotherapy; 20% had discontinued steroids.Tolerance was excellent with no cases of anaphylaxis. The commonest adverse event was fever (55%). Eighteen patients developed serum sickness on median day 11 [10-14]. Seven patients had thrombocytopenia; six patients had severe neutropenia. All of these adverse events recovered spontaneously. The overall incidence of delayed graft function was 24%. At 1 yr patient and graft survival were 98 and 95%, respectively, and creatinine was 135 +/- 43 micromol/L. Clinically suspected and biopsy-proven acute rejection were observed in 65 patients (27%) and 34 patients (14%), respectively. There were 62 non-cytomegalovirus (CMV) infections (two fatal) and 81 episodes of CMV infections. Eight malignancies were reported; two possibly related to immunosuppression.These results demonstrate that anti-thymocyte globulin has a safety profile with good tolerability and excellent efficacy." @default.
• W2016175056 created "2016-06-24" @default.
• W2016175056 creator A5008875970 @default.
• W2016175056 creator A5024686737 @default.
• W2016175056 creator A5041246808 @default.
• W2016175056 creator A5060790711 @default.
• W2016175056 date "2003-11-04" @default.
• W2016175056 modified "2023-10-05" @default.
• W2016175056 title "Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy" @default.
• W2016175056 cites W1550111394 @default.
• W2016175056 cites W1963935236 @default.
• W2016175056 cites W1999246730 @default.
• W2016175056 cites W2018100390 @default.
• W2016175056 cites W2022293788 @default.
• W2016175056 cites W2030461805 @default.
• W2016175056 cites W2055808255 @default.
• W2016175056 cites W2058181551 @default.
• W2016175056 cites W2079599351 @default.
• W2016175056 cites W2087317980 @default.
• W2016175056 cites W2109528079 @default.
• W2016175056 cites W2117815681 @default.
• W2016175056 cites W2127596128 @default.
• W2016175056 cites W2147868374 @default.
• W2016175056 cites W2170783570 @default.
• W2016175056 cites W2322951370 @default.
• W2016175056 cites W4237464194 @default.
• W2016175056 doi "https://doi.org/10.1046/j.1399-0012.2003.00102.x" @default.
• W2016175056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14756271" @default.
• W2016175056 hasPublicationYear "2003" @default.
• W2016175056 type Work @default.
• W2016175056 sameAs 2016175056 @default.
• W2016175056 citedByCount "73" @default.
• W2016175056 countsByYear W20161750562012 @default.
• W2016175056 countsByYear W20161750562013 @default.
• W2016175056 countsByYear W20161750562014 @default.
• W2016175056 countsByYear W20161750562015 @default.
• W2016175056 countsByYear W20161750562016 @default.
• W2016175056 countsByYear W20161750562017 @default.
• W2016175056 countsByYear W20161750562018 @default.
• W2016175056 countsByYear W20161750562019 @default.
• W2016175056 countsByYear W20161750562020 @default.
• W2016175056 countsByYear W20161750562022 @default.
• W2016175056 countsByYear W20161750562023 @default.
• W2016175056 crossrefType "journal-article" @default.
• W2016175056 hasAuthorship W2016175056A5008875970 @default.
• W2016175056 hasAuthorship W2016175056A5024686737 @default.
• W2016175056 hasAuthorship W2016175056A5041246808 @default.
• W2016175056 hasAuthorship W2016175056A5060790711 @default.
• W2016175056 hasConcept C126322002 @default.
• W2016175056 hasConcept C141071460 @default.
• W2016175056 hasConcept C197934379 @default.
• W2016175056 hasConcept C2776694085 @default.
• W2016175056 hasConcept C2776760755 @default.
• W2016175056 hasConcept C2777063308 @default.
• W2016175056 hasConcept C2777630719 @default.
• W2016175056 hasConcept C2778375690 @default.
• W2016175056 hasConcept C2779134260 @default.
• W2016175056 hasConcept C2780252810 @default.
• W2016175056 hasConcept C2780303639 @default.
• W2016175056 hasConcept C2780306776 @default.
• W2016175056 hasConcept C2780882860 @default.
• W2016175056 hasConcept C2781307858 @default.
• W2016175056 hasConcept C2911091166 @default.
• W2016175056 hasConcept C71924100 @default.
• W2016175056 hasConcept C90924648 @default.
• W2016175056 hasConceptScore W2016175056C126322002 @default.
• W2016175056 hasConceptScore W2016175056C141071460 @default.
• W2016175056 hasConceptScore W2016175056C197934379 @default.
• W2016175056 hasConceptScore W2016175056C2776694085 @default.
• W2016175056 hasConceptScore W2016175056C2776760755 @default.
• W2016175056 hasConceptScore W2016175056C2777063308 @default.
• W2016175056 hasConceptScore W2016175056C2777630719 @default.
• W2016175056 hasConceptScore W2016175056C2778375690 @default.
• W2016175056 hasConceptScore W2016175056C2779134260 @default.
• W2016175056 hasConceptScore W2016175056C2780252810 @default.
• W2016175056 hasConceptScore W2016175056C2780303639 @default.
• W2016175056 hasConceptScore W2016175056C2780306776 @default.
• W2016175056 hasConceptScore W2016175056C2780882860 @default.
• W2016175056 hasConceptScore W2016175056C2781307858 @default.
• W2016175056 hasConceptScore W2016175056C2911091166 @default.
• W2016175056 hasConceptScore W2016175056C71924100 @default.
• W2016175056 hasConceptScore W2016175056C90924648 @default.
• W2016175056 hasIssue "6" @default.
• W2016175056 hasLocation W20161750561 @default.
• W2016175056 hasLocation W20161750562 @default.
• W2016175056 hasOpenAccess W2016175056 @default.
• W2016175056 hasPrimaryLocation W20161750561 @default.
• W2016175056 hasRelatedWork W1517986751 @default.
• W2016175056 hasRelatedWork W1600771015 @default.
• W2016175056 hasRelatedWork W1968059227 @default.
• W2016175056 hasRelatedWork W1994374683 @default.
• W2016175056 hasRelatedWork W2151417740 @default.
• W2016175056 hasRelatedWork W2438248743 @default.
• W2016175056 hasRelatedWork W2773942294 @default.
• W2016175056 hasRelatedWork W3041755577 @default.
• W2016175056 hasRelatedWork W4225122360 @default.
• W2016175056 hasRelatedWork W4229058272 @default.
• W2016175056 hasVolume "17" @default.

• next